The Diazine Ring Is One Of The Cyclos In A Bicyclo Ring System Patents (Class 544/116)
-
Patent number: 7132419Abstract: A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C1–C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1–C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R10, CON(R12)2, OCON(R12), SR10, SOR11, SO2R11, SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO2R11)2 NR10(CH2)nCN, NR10COR11, OCOR11 or COR10; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C1–C6 alkoxy, C1–C6 alkyl, SR10 and N(R12)2; Q is C1–C6 alkylene which is unsubstituted or substituted by (i) C1–C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not ? to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R12); R8 and R9, which are the same or different, are each hydrogen or C1–C6 alkyl, or R8 and R9 together with the nitrogen atom to which they are attachType: GrantFiled: December 30, 2004Date of Patent: November 7, 2006Assignee: Xenova LimitedInventors: John Milton, Nigel Vicker, Adrian Folkes, Shouming Wang, William Alexander Denny
-
Patent number: 7115615Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R1, n, R2 and R3 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.Type: GrantFiled: August 15, 2001Date of Patent: October 3, 2006Assignee: AstraZenecaInventors: Laurent Francois Andre Hennequin, Patrick Ple, Christine Marie Paul Lambert
-
Patent number: 7098330Abstract: This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2 and R2? are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.Type: GrantFiled: September 14, 2001Date of Patent: August 29, 2006Assignee: Vertex Pharmaceuticals IncorporatedInventors: David Bebbington, Hayley Binch, Ronald Knegtel, Julian M. C. Golec, Sanjay Patel, Jean-Damien Charrier, David Kay, Robert J. Davies
-
Patent number: 7081461Abstract: The use of a compound of formula (I) or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, NH or NR8 where R8 is hydrogen or C1-6alkyl; Ra is a 3-quinoline group or a group of sub-formula (i) where R5, R6 and R7 are various specific organic groups, in the preparation of a medicament for use in the inhibtion of aurora 2 kinase. Novel compounds of formula (I) and pharmaceutical compositions useful in the treatment of cancer are also described and claimed.Type: GrantFiled: September 18, 2000Date of Patent: July 25, 2006Assignee: AstraZeneca ABInventors: Andrew Austen Mortlock, Nicholas John Keen
-
Patent number: 7056917Abstract: A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH?CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)?C(R9)— (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.Type: GrantFiled: April 26, 2001Date of Patent: June 6, 2006Assignees: Daiichi Pharmaceutical Co., Ltd., Trine Pharmaceuticals, Inc.Inventors: Kiyoshi Nakayama, Masami Ohtsuka, Haruko Kawato, William Watkins, Jason Zhang, Monica Palme, Aesop Cho
-
Patent number: 7045526Abstract: The present invention relates to compounds of formula I: wherein R1, R2, and R3 have the meanings indicated in the specification, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases such as cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses, or atherosclerosis. Compounds of formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds of formula I, methods of therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise at least one compound of formula I.Type: GrantFiled: October 1, 2003Date of Patent: May 16, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Ursula Schindler, Karl Schönafinger, Hartmut Strobel
-
Patent number: 7030112Abstract: Disclosed are pyrrolopyridazine compounds of the formula, wherein the substituents are defined herein, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.Type: GrantFiled: September 26, 2003Date of Patent: April 18, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, Carl R. Illig, Kenneth Jerome Wilson, Jinsheng Chen, Sanath K. Meegalla, Mark James Wall
-
Patent number: 7019011Abstract: The present invention relates to novel derivatives of general formula (I) in which R3 is a (1–6C)alkyl, aryl, aryl(1–6C)alkyl, heteroaryl, heteroaryl(1–6C)alkyl, aryl or heteroaryl fused to a (1–10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(?NH)R1 or C(?NH)NR1 radical; R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1–6C)alkyl, (1–6C)alkoxy, aryl, aryl(1–6C)alkyl, heteroaryl, heteroaryl(1–6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.Type: GrantFiled: September 4, 2003Date of Patent: March 28, 2006Assignee: Aventis Pharma S.A.Inventors: Dominique Lesuisse, Gilles Dutruc-Rosset, Franck Halley, Didier Babin, Thomas Rooney, Gilles Tiraboschi
-
Patent number: 6977255Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: GrantFiled: January 24, 2001Date of Patent: December 20, 2005Assignee: Kinacia Pty. Ltd.Inventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yap, Hishani Parbaharan, Phil Thompson
-
Patent number: 6924284Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula: or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q1, Q2 and Y are those defined herein.Type: GrantFiled: August 15, 2002Date of Patent: August 2, 2005Assignees: ICOS Corporation, Deltagen Research Labs, LLCInventors: Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie E. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin
-
Patent number: 6900220Abstract: This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X—Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.Type: GrantFiled: January 2, 2002Date of Patent: May 31, 2005Assignee: Syntex (U.S.A.) LLCInventors: Cyrus Kephra Becker, Joan Marie Caroon, Chris Richard Melville, Fernando Padilla, Jürg Roland Pfister, Xiaoming Zhang
-
Patent number: 6897213Abstract: Novel quinazolinone derivatives with good binding affinity for the CCK-A and CCK-B receptors, pharmaceutical compositions containing them and methods of using them are taught. The compounds are useful agents to suppress appetite, reduce gastric acid secretion, and the like.Type: GrantFiled: March 7, 1997Date of Patent: May 24, 2005Assignee: Warner-Lambert CompanyInventor: Janak Khimchand Padia
-
Patent number: 6890924Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: June 18, 2001Date of Patent: May 10, 2005Assignee: Pfizer IncInventors: John Charles Kath, Joel Morris, Samit Kumar Bhattacharya
-
Patent number: 6864259Abstract: The present invention provides compounds of Formula (I): wherein R1-R6 and K have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antibacterial agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.Type: GrantFiled: May 29, 2002Date of Patent: March 8, 2005Assignee: Warner-Lambert CompanyInventors: Edmund Lee Ellsworth, Kim Marie Hutchings, Dai Nguyen, Rajeshwar Singh, Howard Daniel Hollis Showalter
-
Publication number: 20040254181Abstract: Derivatives of 9-deazaguanine are prepared by reacting an aldehyde or ketone with a dialkylaminomalonate to form the corresponding enamine. The enamine is then reacted with a base to form a cyclic pyrrole. The cyclic pyrrole is reacted with an urea compound or a derivative of carbamimidoic acid to provide a protected guanidino compound. The guanidino is converted to the desired 9-deazaguanine derivative by reacting with trifluoracetic acid or with an alkoxide or hydroxide followed by neutralization with an acid.Type: ApplicationFiled: June 29, 2004Publication date: December 16, 2004Applicant: BioCryst Pharmaceuticals, Inc.Inventors: Arthur J. Elliott, David A. Walsh, Philip E. Morris
-
Publication number: 20040176594Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomeruloscierosis.Type: ApplicationFiled: March 18, 2004Publication date: September 9, 2004Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
-
Patent number: 6787650Abstract: A compound of the formula: [wherein R1 is a hydrocarbon group which may be substituted; R2 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; R3 is halogen atoms, a carbamoyl group which may be substituted, a sulfamoyl group which may be substituted, an acyl group derived from sulfonic acid, a C1-4 alkyl group which may be substituted, a C1-4 alkoxy group which may be substituted, an amino group which may be substituted, a nitro group or a cyano group; R4 is hydrogen atoms or a hydroxy group; n is 0 or 1; and p is 0 or 1 to 4]; or a salt thereof, has potent CCR5 antagonistic activity and can be advantageously used as a medicament for inhibition of HIV infection to human peripheral blood mononuclear cells, especially for the treatment or prevention of AIDS.Type: GrantFiled: April 5, 2002Date of Patent: September 7, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Osamu Kurasawa, Shinichi Imamura, Shohei Hashiguchi, Osamu Nishimura, Naoyuki Kanzaki, Masanori Baba
-
Patent number: 6770641Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.Type: GrantFiled: June 10, 2003Date of Patent: August 3, 2004Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
-
Publication number: 20040132727Abstract: There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy.Type: ApplicationFiled: October 25, 2002Publication date: July 8, 2004Inventors: Teruyuki Sakai, Terufumi Senga, Takayuki Furuta, Atsushi Miwa
-
Patent number: 6759410Abstract: The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines of formula (1), or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.Type: GrantFiled: May 10, 2002Date of Patent: July 6, 2004Assignee: SmithLine Beecham CorporationInventors: Jerry L. Adams, Michael J. Bower, Ralph Hall, Don Edgar Griswold, David C. Underwood
-
Publication number: 20040127707Abstract: The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are PDE4/7 inhibitors.Type: ApplicationFiled: October 23, 2003Publication date: July 1, 2004Inventor: Geert Jan Sterk
-
Patent number: 6756371Abstract: The compounds of formula (I) in which R1, R2, A, B and Ar have the meanings as given in the description are novel effective PDe4 inhibitorsType: GrantFiled: April 12, 2002Date of Patent: June 29, 2004Assignee: Altana Pharma AGInventor: Geert Jan Sterk
-
Publication number: 20040121998Abstract: This invention concerns compounds of formula 1Type: ApplicationFiled: August 26, 2003Publication date: June 24, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Charles Huang, Keith M. Wilcoxen, Chen Chen, Mustapha Haddach, James R. McCarthy
-
Publication number: 20040116422Abstract: A compound of the formula (I) 1Type: ApplicationFiled: August 21, 2003Publication date: June 17, 2004Inventors: Yasunori Kitano, Eiji Kawahara, Tsuyoshi Suzuki, Daisuke Abe, Masahiro Nakajou, Naoko Ueda
-
Patent number: 6747147Abstract: A compound selected from those of formula (I): wherein: X1, X2, and X3, represent N or —CR3 in which R3 is as described in the description, G1 represents a group selected from those of formulae (i/a) and (i/b): in which R4, R5, and R6 are as defined in the description, G2 represents a group selected from carbon-carbon triple bond, —CH═C═CH—, C═O, C═S, S(O)n1 in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): in which Y1 represents O, S, —NH or —N alkyl, and Y2 represents O, S, —NH or —N alkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Z1 represents —CR9R10, wherein R9 and R10 are as defined in the description, A represents a ring system, R1 represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d): in which p, Z2, B, q and G3 are as deType: GrantFiled: April 16, 2003Date of Patent: June 8, 2004Assignee: Warner-Lambert CompanyInventor: Jack Jie Li
-
Publication number: 20040092515Abstract: Compounds of the formula I: 1Type: ApplicationFiled: August 27, 2003Publication date: May 13, 2004Inventors: Torbjjorn Lundstedt, Anneli Hallgren, Per Andersson, Anders Hallberg, Malin Graffner Nordberg
-
Patent number: 6730671Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes, for making such novel compounds.Type: GrantFiled: February 13, 2003Date of Patent: May 4, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
-
Patent number: 6730668Abstract: The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines; R1 is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; each R2 unit is independently selected from the group consisting of: a) hydrogen; b) —(CH2)jO(CH2)nR8; c) —(CH2)jNR9aR9b; d) —(CH2)jCO2R10; e) —(CH2)jOCO2R10 f) —(CH2)jCON(R10)2; g) —(CH2)jOCON(R10)2; h) two R2 units can be taken together to form a carbonyl unit; i) and mixtures thereof; R8, R9a, R9b, and R10 are each independently hydrogen, C1-C4 alkyl, and mixtures thereof; R9a and R9b can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R10 units can be take together to form a carbocyclic or heterocyclic ringType: GrantFiled: September 18, 2002Date of Patent: May 4, 2004Assignee: The Procter & Gamble CompanyInventors: Michael Philip Clark, Matthew John Laufersweiler, Jane Far-Jine Djung, Michael George Natchus, Biswanath De
-
Publication number: 20040072850Abstract: The present invention relates to compounds of formula I: 1Type: ApplicationFiled: June 27, 2003Publication date: April 15, 2004Inventors: Ronald Knegtel, Michael Mortimore, John Studley, David Millan
-
Publication number: 20040063690Abstract: The present invention relates to compounds of formula I: 1Type: ApplicationFiled: October 1, 2003Publication date: April 1, 2004Applicant: AVENTIS PHARMA DEUTSCHLAND GmBHInventors: Ursula Schindler, Karl Schonafinger, Hartmut Strobel
-
Publication number: 20040063940Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: June 26, 2003Publication date: April 1, 2004Applicant: Pfizer IncInventors: Spiros Liras, Martin P. Allen, Barbara E. Segelstein
-
Publication number: 20040048850Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) arc able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compounds of formula (I).Type: ApplicationFiled: September 12, 2003Publication date: March 11, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
-
Publication number: 20040044204Abstract: Quinazolines of the formula I, in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists.Type: ApplicationFiled: March 20, 2003Publication date: March 4, 2004Inventors: Werner Mederski, Ralf Devant, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R Player, Edward Jaeger, Richard Soll
-
Patent number: 6699861Abstract: Dihydroquinazoline derivatives of the formula where R3 is —(CH2)p—A where p is from 1 to 4 and A is a 5- or 6-membered N-containing heterocyclic ring attached via the N atom or A is —NA′A″ wherein A′ and A″ are the same or different and are each a C1-C4 alkyl group or their pharmaceutically acceptable salts possessing anti-cancer activity.Type: GrantFiled: October 19, 2001Date of Patent: March 2, 2004Assignee: Cancer Research Technology LimitedInventors: Lorraine Skelton, Vassilis Bavetsias, Ann Jackman
-
Publication number: 20040034032Abstract: Compounds of formula I, 1Type: ApplicationFiled: August 13, 2003Publication date: February 19, 2004Applicant: Pfizer IncInventors: Alan John Collis, David Nathan Fox
-
Publication number: 20040034022Abstract: There are described polymorphic forms/hydrates of N-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride, processes for their preparation, as well as the use of the same for the preparation of medicaments with irreversible tyrosine kinase inhibiting action.Type: ApplicationFiled: April 4, 2003Publication date: February 19, 2004Inventors: Hubert Barth, Klaus Steiner, Simon Schneider, Dietmar Huls, Andreas Muhlenfeld, Manfred Westermayer
-
Publication number: 20040029859Abstract: Compounds of formula (I): 1Type: ApplicationFiled: March 12, 2003Publication date: February 12, 2004Applicant: Pfizer Inc.Inventors: Julian Blagg, Michael Jonathan Fray, Mark Llewellyn Lewis, John Paul Mathias, Mark Henryk Stefaniak, Alan Stobie
-
Publication number: 20040014755Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.Type: ApplicationFiled: January 10, 2003Publication date: January 22, 2004Inventors: Dhanapalan Nagarathnam, Uday Khire, Davoud Asgari, Jianxing Shao, Xiao-Gao Liu, Chunguang Wang, Barry Hart, Olaf Weber, Mark Lynch, Lei Zhang, Lei Wang
-
Publication number: 20040006078Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.Type: ApplicationFiled: October 1, 2002Publication date: January 8, 2004Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
-
Publication number: 20030229068Abstract: Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: ApplicationFiled: May 27, 2003Publication date: December 11, 2003Inventors: Qi Huang, Matthew Kaller, Thomas Nguyen, Mark H. Norman, Robert Rzasa, Hui-Ling Wang, Wenge Zhong
-
Publication number: 20030220332Abstract: The invention provides compounds of formula (I), 1Type: ApplicationFiled: June 4, 2003Publication date: November 27, 2003Applicant: Pfizer Inc.Inventors: Alan John Collis, David Nathan Abraham Fox, Julie Newman
-
Publication number: 20030216389Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.Type: ApplicationFiled: November 8, 2002Publication date: November 20, 2003Inventors: Alan D. Roberton, Shaun Jackson, Vijaya Kenche, Cindy Yap, Hishani Parbaharan, Phil Thompson
-
Patent number: 6649620Abstract: Compounds of formula I, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents an aryl group or a heteroaryl group, optionally substituted by C1-4 alkyl or SO2NH2; R3 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing at least one heteroatom selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula Ia, or represents a chain of formula Ib, and pharmaceutically acceptable salts thereof, are useful in the treatment of a variety of disorders including benign prostatic hyperplasia.Type: GrantFiled: September 23, 2002Date of Patent: November 18, 2003Assignee: Pfizer Inc.Inventors: Alan John Collis, David Nathan Fox
-
Publication number: 20030212055Abstract: The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, niType: ApplicationFiled: January 22, 2003Publication date: November 13, 2003Inventor: Laurent Francois Andre Hennequin
-
Patent number: 6645971Abstract: A compound given by general formula (1): [wherein T represents oxygen or sulfur atom, Y represents alkyl, cycloalkyl group, etc., ring W represents benzene ring, etc., R1 and R2 represent independently hydrogen atom, lower alkyl group, etc., and R3 represents hydrogen atom, alkyl group, etc. Z represents a group given by formula: {wherein A1 and A2 represent independently hydrogen atom, alkyl group, etc. and G represents straight chain alkylene having 1-6 of the carbon number, etc.} or a group given by formula: {wherein n represents 0, 1 or 2, ring E represents 4-8 membered saturated heterocyclic ring containing nitrogen atom(s), and A3 represents hydrogen atom, alkyl group, etc.}], its prodrug or pharmaceutically acceptable salt thereof is an antagonist against muscarinic receptor that is useful as anticholinergic medicaments, and therefore it is useful as pollakiuria or urinary incontinence remedy.Type: GrantFiled: April 10, 2001Date of Patent: November 11, 2003Assignee: Sumitomo Pharmaceuticals Company LimitedInventors: Masami Muraoka, Kazuki Matsui, Koji Morishita, Naohito Ohashi
-
Publication number: 20030207879Abstract: The present invention relates generally to compounds of formula (IA): (IA) 1Type: ApplicationFiled: February 3, 2003Publication date: November 6, 2003Inventors: Pier Giovanni Baraldi, Pier A. Borea
-
Patent number: 6642242Abstract: The invention provides compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents one or more groups independently selected from H, halogen, C1-4 alkoxy and CF3; in addition, R2 and one R3 group may together represent —OCH2—, the methylene group being attached to the ortho-position of the pendant phenyl ring; R4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof.Type: GrantFiled: March 19, 2001Date of Patent: November 4, 2003Assignee: Pfizer Inc.Inventors: Alan John Collis, David Nathan Abraham Fox, Julie Newman
-
Publication number: 20030199513Abstract: The invention relates to the use of cinnoline derivatives of formula (I) 1Type: ApplicationFiled: December 5, 2002Publication date: October 23, 2003Applicant: ZENECA LIMITEDInventors: Andrew Peter Thomas, Laurent Francois Andre Hennequin
-
Patent number: 6635639Abstract: Described are compounds having formula I or II: wherein: X is N, and Ak represents a C1-3 alkylene chain; and a salt, solvate or prodrug thereof.Type: GrantFiled: February 13, 2002Date of Patent: October 21, 2003Assignee: NPS Allelix Corp.Inventors: Jalaj Arora, Louise Edwards, Methvin Issac, Anne O'Brien, Abdelmalik Slassi, Ashok Tehim, Tao Xin
-
Patent number: 6632813Abstract: The invention provides compounds with antagonism against excitatory amino acid receptors, in particular, AMPA receptor having 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof as effective ingredients, and processes for the preparation of both. The compounds are 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives represented by the formula (1) where A denotes a single bond or methylene (CH2), Y denotes a nitrogen atom or ═CH—, V denotes a single bond or methylene (CH2), T denotes a hydroxyl group, amino group, lower alkoxycarbonyl group, carboxyl group, aldehyde group or the like, Q denotes a halogen atom, lower alkyl group or lower alkoxy group, and R1 denotes a hydroxyl group, lower alkoxy group or the like, and addition salts thereof.Type: GrantFiled: August 22, 2001Date of Patent: October 14, 2003Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yasuo Takano, Futoshi Shiga, Tsuyoshi Anraku, Kazunori Fukuchi